UK markets close in 7 hours 51 minutes
  • FTSE 100

    7,093.31
    +41.83 (+0.59%)
     
  • FTSE 250

    23,755.22
    +146.43 (+0.62%)
     
  • AIM

    1,271.43
    +4.45 (+0.35%)
     
  • GBP/EUR

    1.1692
    +0.0031 (+0.26%)
     
  • GBP/USD

    1.3688
    +0.0008 (+0.06%)
     
  • BTC-GBP

    32,028.21
    +1,512.56 (+4.96%)
     
  • CMC Crypto 200

    1,091.84
    -11.22 (-1.02%)
     
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • DOW

    34,798.00
    +33.20 (+0.10%)
     
  • CRUDE OIL

    74.80
    +0.82 (+1.11%)
     
  • GOLD FUTURES

    1,758.90
    +7.20 (+0.41%)
     
  • NIKKEI 225

    30,240.06
    -8.75 (-0.03%)
     
  • HANG SENG

    24,183.76
    -8.40 (-0.03%)
     
  • DAX

    15,670.70
    +138.95 (+0.89%)
     
  • CAC 40

    6,673.71
    +35.25 (+0.53%)
     

Kizoo Portfolio Company Underdog Awarded 'Innovation Passport' by UK Regulators

·3-min read

DGAP-News: KIZOO Technology Capital GmbH / Key word(s): Miscellaneous
08.09.2021 / 09:00
The issuer is solely responsible for the content of this announcement.

Kizoo Portfolio Company Underdog Awarded 'Innovation Passport' by UK Regulators

Mountain View, CA, U.S., September 8, 2021 - Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo is one of the first companies to be awarded the Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to Underdog's potentially groundbreaking treatment option for the prevention of heart attacks and stroke.

ILAP, introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) in January, is designed to accelerate development of and access to promising medicines of significant potential public health benefit. The ILAP program also provides the potential for significant downstream regulatory advantages, including rolling clinical reviews, accelerated assessment, and supervised early reimbursed use under adaptive authorization.

Accounting for up to 40% of deaths in Europe and the United States with annual treatment costs over £29 billion in the UK alone, cardiovascular disease is by far the world's most life-threatening condition, and its primary cause is atherosclerosis. Underdog is developing engineered cyclodextrins for the treatment of atherosclerosis by removing arterial plaque to clear the non-degradable cholesterol that accumulates within cells in the arterial walls.

"I believe the MHRA is sending a powerful message by reviewing and admitting preclinical stage programs like ours into ILAP," noted Mike Kope, Underdog Co-CEO. "The advice and consultation we'll receive will be invaluable to the success of the program and our long-term goal to deliver a simple and affordable preventive therapy for the world. The ILAP program will allow us to advance to a world without heart attacks and stroke a lot faster."

About KIZOO

Kizoo provides mentoring, seed and follow-on financing with a focus on rejuvenation biotech. Having been entrepreneurs, VCs, and mentors in both high-growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech. We see it as a young industry that will eventually outgrow today's largest technology markets.

As part of the Forever Healthy Group, Kizoo directly supports the creation of startups turning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others.

Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference.

Further information, please visit:www.kizoo.com and www.forever-healthy.org.

About Underdog

Underdog Pharmaceuticals, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com.

 

Media Contact for Kizoo:
Frank Schueler
Managing Director
Kizoo Technology Capital
fs@kizoo.com

Media Contact for Underdog:
Mike Cope
Co-CEO
Underdog Pharmaceuticals Inc
press@underdogpharma.com


08.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

KIZOO Technology Capital GmbH

Amalienbadstraße 41

76227 Karlsruhe

Germany

Phone:

+49 721 5160 0

E-mail:

info@kizoo.com

Internet:

www.kizoo.com

EQS News ID:

1231846


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting